IL-1Ra inhibits the activity of both IL-1α and IL-1β and is clinically approved as the drug anakinra for treating autoimmune disorders such as cryopyrin-associated periodic syndrome (CAPS), Still’s disease, familial Mediterranean fever (FMF), rheumatoid arthritis, and periodic fever syndromes [9,10]. The gene discussed is IL1A; the disease is familial Mediterranean fever.